This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

Regeneron Pharmaceuticals took a modest hit as BDF Gestion reduced its stake by 11.5% in the first quarter, now holding $2.8 ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The stock's fall snapped a two-day winning streak.

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $68.00, ...

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

Pallas Capital Advisors jumped into the biotech game by purchasing $426,000 worth of Regeneron Pharmaceuticals shares during ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.